new glp 1 receptor agonists GLP-1 as Treatments for Type 2 Diabetes new glp 1 agonist In

Other oral compounds like CT-996 / RG 6652 showed a clinically meaningful weight reduction of 6-7% in four weeks among participants without T2D, and GSBR-1290 has demonstrated favourable safety, tolerability and efficacy results

Learn what GLP-1 medications are, how they work, and which conditions they are used to treat.

The European Cardiovascular Health Plan Roadmap from the European Alliance was published earlier in 2025 and calls for comprehensive approaches to incorporate the recognition of obesity as a trigger for cardiovascular disease

The glp-1 agonists market is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026 to 2032.

This review describes the basic and clinical pharmacology of orally administered semaglutide

Background Establishing whether there is a potential relationship between glucagon-like peptide 1 receptor agonists (GLP-1RAs) and suicidal or self-injurious behaviors (SSIBs) is crucial for public safety